Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,333 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control label Clear all
Completed Phase 4 Interventional Results available

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

NCT04583735
View directory record Official record
Conditions
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
Interventions
TEPEZZA, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

NCT02137850
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 6 Years · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
34
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain Training in Preterm Children at Risk for Inattention, Hyperactivity, and Executive Function Impairment

NCT02588391
View directory record Official record
Conditions
Premature Birth
Interventions
Brain Training (Active), Brain Training (Passive), Brain Training (Active or Passive)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 5 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 21, 2026, 7:32 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117
View directory record Official record
Conditions
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Interventions
Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older · Male only
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
36
States / cities
Tucson, Arizona • Duarte, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 21, 2026, 7:32 AM EDT
Recruiting Phase 3 Interventional

Neoadjuvant Darovasertib in Primary Uveal Melanoma

NCT07015190
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Darovasertib, Primary Local Therapy
Drug · Procedure
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
35
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

NCT05966090
View directory record Official record
Conditions
Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, HZ/su vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
11
States / cities
Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of EXPAREL in Comparison to Standard of Care for the Treatment of Post Operative Dental Implant Pain

NCT02533440
View directory record Official record
Conditions
Postoperative Pain
Interventions
EXPAREL and Local Anesthetics, Oral Opioid and Local Anesthetics
Procedure
Lead sponsor
Bellaire Facial Surgery Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Houston, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 21, 2026, 7:32 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

NCT06553768
View directory record Official record
Conditions
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Interventions
Maralixibat, Placebo
Drug · Other
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study

NCT04593823
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix Infusor
Combination Product
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Fairhope, Alabama • Huntsville, Alabama • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

NCT04615273
View directory record Official record
Conditions
Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
Interventions
Lonapegsomatropin, Placebo, Somatropin
Drug · Other
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
23 Years to 80 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?

NCT01526213
View directory record Official record
Conditions
Food-drug Interaction
Interventions
Fexofenadine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 21, 2026, 7:32 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

NCT00412750
View directory record Official record
Conditions
Hepatitis B
Interventions
Telbivudine (LdT), peginterferon alpha-2a
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Characterize the Effect of Heparin on Palifermin Activity

NCT01163097
View directory record Official record
Conditions
Oral Mucositis
Interventions
Palifermin, Heparin
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

NCT03440424
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Lemborexant
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 21, 2026, 7:32 AM EDT
Not listed Not applicable Interventional

The Effect of Magnesium Citrate Supplementation in Restless Legs Syndrome (RLS)

NCT04462796
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Magnesium Citrate
Dietary Supplement
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

NCT02553161
View directory record Official record
Conditions
Depression, Anxiety, Bipolar Disorder
Interventions
Escitalopram, Cognitive behavioral Psychotherapy
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Stanford, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth

NCT01662791
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rifaximin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

University of Georgia Mind Your Heart Pilot Study

NCT07670910
View directory record Official record
Conditions
Hypertension (HTN), Obesity & Overweight
Interventions
Mind Your Heart, DASH Diet Education
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

NCT04303780
View directory record Official record
Conditions
KRAS p, G12c Mutated /Advanced Metastatic NSCLC
Interventions
AMG 510, Docetaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
54
States / cities
Anaheim, California • Duarte, California • Long Beach, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .

NCT01077505
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, Oral contraceptive (Brevicon)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 21, 2026, 7:32 AM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

NCT01119846
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 21, 2026, 7:32 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Myasthenia Gravis Inebilizumab Trial

NCT04524273
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
inebilizumab, IV Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
16
States / cities
Orange, California • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 21, 2026, 7:32 AM EDT
Recruiting Phase 3 Interventional

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

NCT07266805
View directory record Official record
Conditions
Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
San Diego, California • Walnut Creek, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 7:32 AM EDT